Tevogen Bio Holdings

TVGN

Market cap $43.8M

WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue.

WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a Management Services Organization (“MSO”).

Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth, and evaluation of revenue-generating acquisitions.

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the “PIPE”) financing with existing investor The Patel Family, LLP for gross proceeds of $3 million.

WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including the near completion of its PredicTcell™ training algorithm and early steps toward commercial readiness.

Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices Target CRO operates across 20+ countries, providing global clinical development capabilities WARREN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices.

WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market.

WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026), taking place March 16–20, 2026, in Atlanta, Georgia.

Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.